Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Petrelli, Nicholas J.
Colangelo, Linda H.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
Goldberg, Richard M.
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Lopa, Samia
Wolmark, Norman

Open PDF

Open link

Publication date

January 2011

DOI

10.17615/wj4v-mg24

Abstract

The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the safety and efficacy of adding bevacizumab to modified FOLFOX6 (mFOLFOX6; ie, infusional/bolus fluorouracil, leucovorin, and oxaliplatin) for the adjuvant treatment of patients with stages II to III colon cancer

Extracted data

We use cookies to provide a better user experience.

Data Protection

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Petrelli, Nicholas J.
Colangelo, Linda H.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
Goldberg, Richard M.
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Lopa, Samia
Wolmark, Norman

Open PDF

Open link

Publication date

January 2011

DOI

10.17615/wj4v-mg24

Abstract

Extracted data

Vincenzi, B
Santini, D
Spoto, C
Venditti, O
Gasparro, S
Zobel, BB
Caricato, M
Valeri, S
Coppola, R
Tonini, G.
RUSSO, Antonio
RIZZO, Sergio

January 2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab+5-fluorou...

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).

Avallone, Antonio
Piccirillo, Maria Carmela
Aloj, Luigi
Nasti, Guglielmo
Delrio, Paolo
Izzo, Francesco
Di Gennaro, Elena
Tatangelo, Fabiana
Granata, Vincenza
Cavalcanti, Ernesta
Maiolino, Piera
Bianco, Francesco
Aprea, Pasquale
De Bellis, Mario
Pecori, Biagio
Rosati, Gerardo
Carlomagno, Chiara
Bertolini, Alessandro
Gallo, Ciro
Romano, Carmela
Leone, Alessandra
Caracò, Corradina
de Lutio di Castelguidone, Elisabetta
Daniele, Gennaro
Catalano, Orlando
Botti, Gerardo
Petrillo, Antonella
Romano, Giovanni M
Iaffaioli, Vincenzo R
Lastoria, Secondo
Perrone, Francesco
Budillon, Alfredo

February 2016

BACKGROUND: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the seco...

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Petrelli, Nicholas J.
Colangelo, Linda H.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
Goldberg, Richard M.
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Lopa, Samia
Wolmark, Norman

January 2011

The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the s...

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Colangelo, Linda H.
Lopa, Samia H.
Petrelli, Nicholas J.
Goldberg, Richard M.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Wolmark, Norman

January 2009

The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the s...

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

André, T.
Vernerey, D.
Im, S.A.
Bodoky, G.
Buzzoni, R.
Reingold, S.
Rivera, F.
Mckendrick, J.
Scheithauer, W.
Ravit, G.
Fountzilas, G.
Yong, W.P.
Isaacs, R.
Österlund, P.
Liang, J.T.
Creemers, G.J.
Rakez, M.
van Cutsem, E.
Cunningham, D.
Tabernero, J.
de Gramont, A.

February 2020

International audienceBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its p...

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

André, T
Vernerey, D
Im, SA
Bodoky, G
Buzzoni, R
Reingold, S
Rivera, F
McKendrick, J
Scheithauer, W
Ravit, G
Fountzilas, G
Yong, WP
Isaacs, R
Österlund, P
Liang, JT
Creemers, GJ
Rakez, M
Van Cutsem, E
Cunningham, D
Tabernero, J
de Gramont, A

February 2020

BACKGROUND: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of im...

Bevacizumab as adjuvant treatment of colon cancer : updated results from the S-AVANT phase III study by the GERCOR Group

Andre, T.
Vernerey, D.
Im, S. A.
Bodoky, G.
Buzzoni, R.
Reingold, S.
Rivera, F.
McKendrick, J.
Scheithauer, W.
Ravit, G.
Fountzilas, G.
Yong, W. P.
Isaacs, R.
Österlund, P.
Liang, J. T.
Creemers, G. J.
Rakez, M.
Van Cutsem, E.
Cunningham, D.
Tabernero, J.
de Gramont, A.

February 2020

Background: The bevacizumab-Avastin (R) adjuVANT (AVANT) study did not meet its primary end point of...

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

de Gramont, Aimery
Van Cutsem, Eric
Schmoll, Hans-Joachim
Tabernero, Josep
Clarke, Stephen
Moore, Malcolm J.
Cunningham, David
Cartwright, Thomas H.
Hecht, J. Randolph
Rivera, Fernando
Im, Seock-Ah
Bodoky, Gyoergy
Salazar, Ramon
Maindrault-Goebel, Frederique
Shacham-Shmueli, Einat
Bajetta, Emilio
Makrutzki, Martina
Shang, Aijing
Andre, Thierry
Hoff, Paulo M

January 2012

Background: Bevacizumab improves the efficacy of oxaliplatin-based chemotherapy in metastatic colore...

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial

Falcone, A.
Salvatore, L.
Boni, L.
Loupakis, F.
Cremolini, C.
Fornaro, L.
Schirripa, M.
CUPINI, STEFANO
Barbara, C.
Safina, V.
Granetto, C.
Fea, E.
Antonuzzo, L.
Boni, C.
Allegrini, G.
Chiara, S.
Amoroso, D.
Bonetti, A.

January 2015

Background: The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-...

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Sikov, William M.
Berry, Donald A.
Perou, Charles M.
Singh, Baljit
Cirrincione, Constance T.
Tolaney, Sara M.
Kuzma, Charles S.
Pluard, Timothy J.
Somlo, George
Port, Elisa R.
Golshan, Mehra
Bellon, Jennifer R.
Collyar, Deborah
Hahn, Olwen M.
Carey, Lisa A.
Hudis, Clifford A.
Winer, Eric P.

January 2015

One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial

Chibaudel, Benoist
Henriques, Julie
Rakez, Manel
Brenner, Baruch
Kim, Tae Won
Martínez-Villacampa, Mercedes
Tabernero Caturla, Josep

October 2020

Quimioteràpia; Supervivència sense malaltia; Càncer de còlonQuimioterapia; Supervivencia sin enferme...

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)

Miller, Kathy D.
O’Neill, Anne
Gradishar, William
Hobday, Timothy J.
Goldstein, Lori J.
Mayer, Ingrid A.
Bloom, Stuart
Brufsky, Adam M.
Tevaarwerk, Amye J.
Sparano, Joseph A.
Le-Lindqwister, Nguyet Anh
Hendricks, Carolyn B.
Northfelt, Donald W.
Dang, Chau T.
Sledge, George W.

September 2018

Purpose Bevacizumab improves progression-free survival but not overall survival in patients with met...

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.

Chibaudel, Benoist
Henriques, Julie
Rakez, Manel
Brenner, Baruch
Kim, Tae Won
Martinez-Villacampa, Mercedes
Gallego-Plazas, Javier
Cervantes, Andres
Shim, Katharine
Jonker, Derek
Guerin-Meyer, Veronique
Mineur, Laurent
Banzi, Chiara
Dewdney, Alice
Dejthevaporn, Thitiya
Bloemendal, Haiko J
Roth, Arnaud
Moehler, Markus
Aranda, Enrique
Van Cutsem, Eric
Tabernero, Josep
Schmoll, Hans-Joachim
Hoff, Paulo M
André, Thierry
de Gramont, Aimery

October 2020

Importance: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage...

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

Vincenzi, B
Santini, D
Spoto, C
Venditti, O
Gasparro, S
Zobel, BB
Caricato, M
Valeri, S
Coppola, R
Tonini, G.
RUSSO, Antonio
RIZZO, Sergio

January 2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab+5-fluorou...

Avallone, Antonio
Piccirillo, Maria Carmela
Aloj, Luigi
Nasti, Guglielmo
Delrio, Paolo
Izzo, Francesco
Di Gennaro, Elena
Tatangelo, Fabiana
Granata, Vincenza
Cavalcanti, Ernesta
Maiolino, Piera
Bianco, Francesco
Aprea, Pasquale
De Bellis, Mario
Pecori, Biagio
Rosati, Gerardo
Carlomagno, Chiara
Bertolini, Alessandro
Gallo, Ciro
Romano, Carmela
Leone, Alessandra
Caracò, Corradina
de Lutio di Castelguidone, Elisabetta
Daniele, Gennaro
Catalano, Orlando
Botti, Gerardo
Petrillo, Antonella
Romano, Giovanni M
Iaffaioli, Vincenzo R
Lastoria, Secondo
Perrone, Francesco
Budillon, Alfredo

February 2016

BACKGROUND: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the seco...

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Petrelli, Nicholas J.
Colangelo, Linda H.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
Goldberg, Richard M.
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Lopa, Samia
Wolmark, Norman

January 2011

The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the s...

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Colangelo, Linda H.
Lopa, Samia H.
Petrelli, Nicholas J.
Goldberg, Richard M.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Wolmark, Norman

January 2009

The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the s...

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

André, T.
Vernerey, D.
Im, S.A.
Bodoky, G.
Buzzoni, R.
Reingold, S.
Rivera, F.
Mckendrick, J.
Scheithauer, W.
Ravit, G.
Fountzilas, G.
Yong, W.P.
Isaacs, R.
Österlund, P.
Liang, J.T.
Creemers, G.J.
Rakez, M.
van Cutsem, E.
Cunningham, D.
Tabernero, J.
de Gramont, A.

February 2020

International audienceBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its p...

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

André, T
Vernerey, D
Im, SA
Bodoky, G
Buzzoni, R
Reingold, S
Rivera, F
McKendrick, J
Scheithauer, W
Ravit, G
Fountzilas, G
Yong, WP
Isaacs, R
Österlund, P
Liang, JT
Creemers, GJ
Rakez, M
Van Cutsem, E
Cunningham, D
Tabernero, J
de Gramont, A

February 2020

BACKGROUND: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of im...

Bevacizumab as adjuvant treatment of colon cancer : updated results from the S-AVANT phase III study by the GERCOR Group

Andre, T.
Vernerey, D.
Im, S. A.
Bodoky, G.
Buzzoni, R.
Reingold, S.
Rivera, F.
McKendrick, J.
Scheithauer, W.
Ravit, G.
Fountzilas, G.
Yong, W. P.
Isaacs, R.
Österlund, P.
Liang, J. T.
Creemers, G. J.
Rakez, M.
Van Cutsem, E.
Cunningham, D.
Tabernero, J.
de Gramont, A.

February 2020

Background: The bevacizumab-Avastin (R) adjuVANT (AVANT) study did not meet its primary end point of...

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

de Gramont, Aimery
Van Cutsem, Eric
Schmoll, Hans-Joachim
Tabernero, Josep
Clarke, Stephen
Moore, Malcolm J.
Cunningham, David
Cartwright, Thomas H.
Hecht, J. Randolph
Rivera, Fernando
Im, Seock-Ah
Bodoky, Gyoergy
Salazar, Ramon
Maindrault-Goebel, Frederique
Shacham-Shmueli, Einat
Bajetta, Emilio
Makrutzki, Martina
Shang, Aijing
Andre, Thierry
Hoff, Paulo M

January 2012

Background: Bevacizumab improves the efficacy of oxaliplatin-based chemotherapy in metastatic colore...

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial

Falcone, A.
Salvatore, L.
Boni, L.
Loupakis, F.
Cremolini, C.
Fornaro, L.
Schirripa, M.
CUPINI, STEFANO
Barbara, C.
Safina, V.
Granetto, C.
Fea, E.
Antonuzzo, L.
Boni, C.
Allegrini, G.
Chiara, S.
Amoroso, D.
Bonetti, A.

January 2015

Background: The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-...

Sikov, William M.
Berry, Donald A.
Perou, Charles M.
Singh, Baljit
Cirrincione, Constance T.
Tolaney, Sara M.
Kuzma, Charles S.
Pluard, Timothy J.
Somlo, George
Port, Elisa R.
Golshan, Mehra
Bellon, Jennifer R.
Collyar, Deborah
Hahn, Olwen M.
Carey, Lisa A.
Hudis, Clifford A.
Winer, Eric P.

January 2015

One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial

Chibaudel, Benoist
Henriques, Julie
Rakez, Manel
Brenner, Baruch
Kim, Tae Won
Martínez-Villacampa, Mercedes
Tabernero Caturla, Josep

October 2020

Quimioteràpia; Supervivència sense malaltia; Càncer de còlonQuimioterapia; Supervivencia sin enferme...

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)

Miller, Kathy D.
O’Neill, Anne
Gradishar, William
Hobday, Timothy J.
Goldstein, Lori J.
Mayer, Ingrid A.
Bloom, Stuart
Brufsky, Adam M.
Tevaarwerk, Amye J.
Sparano, Joseph A.
Le-Lindqwister, Nguyet Anh
Hendricks, Carolyn B.
Northfelt, Donald W.
Dang, Chau T.
Sledge, George W.

September 2018

Purpose Bevacizumab improves progression-free survival but not overall survival in patients with met...

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.

Chibaudel, Benoist
Henriques, Julie
Rakez, Manel
Brenner, Baruch
Kim, Tae Won
Martinez-Villacampa, Mercedes
Gallego-Plazas, Javier
Cervantes, Andres
Shim, Katharine
Jonker, Derek
Guerin-Meyer, Veronique
Mineur, Laurent
Banzi, Chiara
Dewdney, Alice
Dejthevaporn, Thitiya
Bloemendal, Haiko J
Roth, Arnaud
Moehler, Markus
Aranda, Enrique
Van Cutsem, Eric
Tabernero, Josep
Schmoll, Hans-Joachim
Hoff, Paulo M
André, Thierry
de Gramont, Aimery

October 2020

Importance: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage...

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

Vincenzi, B
Santini, D
Spoto, C
Venditti, O
Gasparro, S
Zobel, BB
Caricato, M
Valeri, S
Coppola, R
Tonini, G.
RUSSO, Antonio
RIZZO, Sergio

January 2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab+5-fluorou...

Avallone, Antonio
Piccirillo, Maria Carmela
Aloj, Luigi
Nasti, Guglielmo
Delrio, Paolo
Izzo, Francesco
Di Gennaro, Elena
Tatangelo, Fabiana
Granata, Vincenza
Cavalcanti, Ernesta
Maiolino, Piera
Bianco, Francesco
Aprea, Pasquale
De Bellis, Mario
Pecori, Biagio
Rosati, Gerardo
Carlomagno, Chiara
Bertolini, Alessandro
Gallo, Ciro
Romano, Carmela
Leone, Alessandra
Caracò, Corradina
de Lutio di Castelguidone, Elisabetta
Daniele, Gennaro
Catalano, Orlando
Botti, Gerardo
Petrillo, Antonella
Romano, Giovanni M
Iaffaioli, Vincenzo R
Lastoria, Secondo
Perrone, Francesco
Budillon, Alfredo

February 2016

BACKGROUND: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the seco...

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Abstract

Extracted data

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Abstract

Extracted data

Related items

Related items